Acutaas Chemicals Ltd Q4 FY2026 Concall Summary

Key Takeaways

• 40% revenue surge, margin doubled: Revenue grew 40.3% YoY while EBITDA margin expanded ~1,500 bps to 42.4%, driven by CDMO ramp-up and a recovering BFC business within Specialty Chemicals.
• FY27 guided at 25% growth with stable margins: Management committed to 25% revenue growth and expects to hold EBITDA margin near FY26 levels (~34.5-35%), supported by portfolio upgrades and new product commercialization.
• New verticals are crossing from investment to revenue: Battery chemicals and semiconductors (BFC) are now commercialized and shipping, with the Indichem JV plant pulling forward its timeline; management sees both as independent growth engines by FY28.
• Portfolio reshuffling is deliberate and ongoing: The company is systematically replacing commodity chemical products with higher-value differentiated offerings, using the same infrastructure with slight modifications in a calibrated phased manner.
• What to watch next quarter: Whether the guided 25% FY27 growth holds through the seasonally weak Q1, the pace of electrolyte additive ramp-up quarter-by-quarter, and any concrete revenue numbers for battery chemicals once variables firm up.

Growth Drivers & New Verticals

• CDMO business scaling fast: Four additional products beyond the first Fermion contract have been validated, commercialized and supplied to customers, now awaiting regulatory approval; revenue expected in FY27 with major ramp-up in FY28.
• First CDMO contract is long-term: The initial customer has a 10-year supply contract, and the company targets INR1,000 crores in CDMO revenue by FY28.
• Battery chemicals now commercial: First two products successfully commercialized; two additional products expected at commercial scale in FY27, with meaningful revenue contribution starting slowly in Q1 and ramping through Q4.
• Battery chemistry breadth: The company is working to supply molecules across sodium-ion, lithium and solid-state battery segments, with management noting its target is "even not 1% of the demand" so technology shifts pose limited risk.
• Electrolyte additive plant fully contracted: The Jhagadia plant's first phase is complete and production has started; all capacities are covered by customer contracts for the next 3 years, with contribution adding quarter-by-quarter from Q1 to Q4.
• Third and fourth additives in pipeline: Capex for the third electrolyte additive is ongoing with completion by Q1 FY27; the fourth is in the business development phase.
• Semiconductor shipments have begun: Shipments to Japanese and Korean customers have already started, and the BFC business recovered strongly from Q4 onwards.
• Indichem JV timeline pulled forward: Plant construction now expected to complete in the second half of calendar year 2026, earlier than the previously guided start of CY27; the R&D centre in South Korea is already running and samples have been supplied to customers.
• Indichem margin profile: Management indicated margins should be in line with the BFC business rather than traditional specialty chemicals, though called it premature to give a specific figure.

Naresh Patel: "Overall, I believe that by FY '28, our both business verticals, which are in investment phase now, battery chemicals and semiconductors will evolved into independent self-sustaining growth engines. Each contributing meaningful to our top line along with pharmaceutical intermediates business."

Portfolio Strategy & Margin Structure

• Core pharma intermediates reshuffled: The first phase of strategic portfolio reshuffling in advanced pharmaceutical intermediates was mostly completed during the first 9 months of FY26, driving healthy sequential growth in Q4.
• Commodity-to-specialty migration underway: The next phase involves systematic replacement of commodity chemical products with higher-value differentiated offerings, using existing infrastructure with slight modifications in a calibrated phased manner starting this year.
• Specialty Chemicals margin jump to 29%: Driven by very strong recovery in the BFC business (high EBITDA margin) from Q4 onwards; the segment includes traditional specialty chemicals plus semiconductor/electronics and battery chemicals.
• BFC recovery sustainable: Strong pickup in Q4 with similar visibility for FY27; no large capex needed for this business.
• FY27 margin confidence: Management expects EBITDA margin similar to FY26 (around 34.5-35%), as margin is a function of product mix and a similar mix is expected.
• Goodwill breakdown: INR104 crores total goodwill comprises ~INR48 crores from the past BFC acquisition and the remainder from the Indichem JV, where the partner contributed capital at par value for 25% equity, so 25% of the INR190 crore investment went to goodwill per accounting standards.

Bharat Shah: "If we don't want the business to be commoditized, investing into the future to build it is an absolutely very vital one. And we have done very well by taking up intelligent bets and we have to consolidate. So I think we shouldn't get deterred by our current size in order to build our future, which can be very exciting."

Segment Performance

• Gross margin expanded 1,467 bps YoY to 62%, driven by improved product mix; EBITDA margin up 1,487 bps to 42.4% on gross margin expansion and operating leverage.
• Working capital rose to 120 days from 114 days: improvement in debtor and inventory days was offset by lower payable days.

Seasonality & Revenue Cadence

• Established 15-year pattern: Q1 is historically the weakest quarter, with revenue increasing sequentially through Q4; H1 typically contributes ~40% of the top line and H2 ~60%.
• Pattern expected to persist in FY27: Management confirmed this seasonality will continue despite the Fermion ramp-up, noting the company has over 600 customers and 100+ products, not just one contract.
• Growth drivers for next 3 years: Pharma intermediates remain the biggest engine, followed by electrolyte additives and the semiconductor business (BFC now, Indichem in 2-3 years).

Naresh Patel: "Sir, this is my company history is that we have always -- Q1 is lower than Q2, Q2 is lower than Q3. Q3 is low than Q4. In last 15 years, it is like that. We are not only dealing with Fermion. We have more than 600 customers. So each customer has different require at different time, and we have more than 100 products. So it's my company's seasonality and working like that."

Capex & Infrastructure

• Electrolyte additive plant: First phase completed; second phase ongoing with completion expected by Q1 FY27.
• Pilot plant capex: Slightly delayed due to equipment arrival; now expected completion by Q2 FY27.
• R&D centre expansion: Planned 10x capacity expansion with dedicated sections for pharmaceuticals, battery chemicals, semiconductor, electronics and cosmetics; capex figures yet to be finalized.
• Land acquisition: Actively evaluating land acquisition opportunities for new infrastructure to support long-term growth.
• FY27 capex estimate: Spillover of FY26 capex (~INR50 crores) plus maintenance capex (~INR40 crores) plus the R&D centre, with figures to be finalized and updated at a relevant time.

Pushback & Unanswered

• Battery chemicals revenue target declined: Management called the FY27 contribution "meaningful" but refused to put a number on it, citing "many variables."
• Goodwill recoverability left vague: When asked for the specific basis for confidence in recovering INR104 crores of goodwill, management offered a general confidence statement without a recoverability timeline or specific metrics.
• Indichem margin guidance deferred: Called "very premature" since the plant is in construction phase; management only offered that margins should be in line with the BFC business, not traditional specialty chemicals.
• Electrolyte additive utilization undisclosed: Management declined to give a capacity utilization figure for FY27, stating only that production has started and will add quarter-by-quarter.
• R&D centre capex not finalized: Figures are still being worked out and will be updated later.
• Fermion ramp-up details deflected: Management pointed analysts to Bayer/Orion presentations, saying "those things are already available."

Guidance & Commitments

Key Metrics